Last edited by Kagajora
Monday, July 20, 2020 | History

2 edition of Optimizing Antiplatelet Therapy in Atherothrombotic Patients found in the catalog.

Optimizing Antiplatelet Therapy in Atherothrombotic Patients

J. Boeousslavsky

Optimizing Antiplatelet Therapy in Atherothrombotic Patients

Satelite Symposium to the 9th European Stroke Conference, Vienna, May 2000 (Cerebrovascular Diseases 2001, 2)

by J. Boeousslavsky

  • 376 Want to read
  • 7 Currently reading

Published by Not Avail .
Written in English

    Subjects:
  • Cardiovascular medicine,
  • Neurology & clinical neurophysiology,
  • Cerebrovascular Diseases,
  • Medical,
  • Medical / Nursing,
  • Medical / Neurology,
  • Cardiology,
  • Neurology - General

  • Edition Notes

    ContributionsJ. D. Easton (Editor)
    The Physical Object
    FormatPaperback
    Number of Pages26
    ID Numbers
    Open LibraryOL12931292M
    ISBN 103805572352
    ISBN 109783805572354

      This editorial refers to ‘Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors’ †, by L. Pasea et al., on page The cardiovascular field is the medical discipline publishing the largest number of randomized clinical trials (RCTs Cited by: 2. Atherothrombotic events and clopidogrel therapy The key question in such patients is whether the antiplatelet therapy should be maintained throughout the period or slopped before the operation Author: Micheal Guirguis.

      Despite a large volume of evidence supporting the use of dual antiplatelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Clinical trials have varied markedly in the duration of therapy, both across and within trials. Recent systematic reviews and meta-analyses suggest that shorter durations of dual antiplatelet Cited by: The Twelve or 30 Months After Dual Anti-Platelet Therapy After Drug-Eluting Stents (DAPT) trial compared 18 months of DAPT versus aspirin alone in over 9, patients who had tolerated 12 months of DAPT following PCI. 7 Similar to the CHARISMA post-hoc analysis, DAPT patients benefited from a reduction in thrombotic events (% DAPT patients.

      While these data suggest that extended dual antiplatelet therapy improves CV outcomes in patients after ACS, predominately by reducing de novo atherothrombotic ischemic events, additional studies are needed to identify patients treated with PCI likely to derive the greatest benefit of extended-duration dual antiplatelet therapy following ACS. Dual antiplatelet therapy for all CVD patients? Currently used antiplatelet drugs are summarised in table 1 and pivotal clinical trials of dual antiplatelet therapy in table 2. The Clopidogrel for High Atherothrombotic Risk and Ischaemia Stabilisation, Management and Author: Ranil de Silva.


Share this book
You might also like
Phantoms, legends, customs and superstitions of the sea.

Phantoms, legends, customs and superstitions of the sea.

The exchange

The exchange

The Complete Beauty Workshop

The Complete Beauty Workshop

Law of trusts in Canada

Law of trusts in Canada

Jesuits in profile

Jesuits in profile

Drainage-return, surface-water withdrawal, and land-use data for the Sacramento-San Joaquin Delta, with emphasis on Twitchell Island, California

Drainage-return, surface-water withdrawal, and land-use data for the Sacramento-San Joaquin Delta, with emphasis on Twitchell Island, California

VHF/UHF manual.

VHF/UHF manual.

In China, 1920-1921

In China, 1920-1921

Fritz Saxl, 1890-1948

Fritz Saxl, 1890-1948

AMERICAN CARD TECHNOLOGY, INC.

AMERICAN CARD TECHNOLOGY, INC.

Dionysus in Paris

Dionysus in Paris

Optimizing Antiplatelet Therapy in Atherothrombotic Patients by J. Boeousslavsky Download PDF EPUB FB2

Antiplatelet Therapy. The Antiplatelet Trialists Collaboration (ATC) published a meta-analysis of trials with patients in comparison of antiplatelet therapy versus controls, and in comparison of different antiplatelet regimens. The main results were summarized as a reduction of serious vascular events (which include non-fatal MI, non-fatal stroke, or vascular death) by about 25%.

Antiplatelet therapy remains a cornerstone in the management of patients with atherothrombotic diseases. The use of single or dual antiplatelet therapy (DAPT) regimens has been effective in reducing cardiovascular events among patients with stable coronary artery disease (CAD), acute coronary syndrome (ACS), peripheral artery disease (PAD), and cerebrovascular by: 4.

Optimizing Oral Antiplatelet Therapy in Acute Coronary Syndrome Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology) PRESENTATION Update on Oral Antiplatelet Therapy in Acute Coronary Syndrome OVERVIEW Antiplatelet therapy has been a cornerstone in the treatment of patients with acute coronary syndrome (ACS) since the s.

Secondary prevention strategies for patients with atherothrombosis are discussed, highlighting current guideline recommendations and programs designed to encourage a continuum of care from the acute to the ambulatory by: Antiplatelet and anticoagulant therapy Start aspirin, mg/d, and continue indefinitely in all patients without contraindications For CABG patients, aspirin ( mg/d) should be started within 48 h after surgery; doses > mg/d can be continued for up to 1 y Clopidogrel, 75 mg/d (in the absence of contraindications), Cited by:   Tailoring antiplatelet therapy in stable (low-risk) PCI patients is difficult as this cohort already has a low frequency of atherothrombotic events.

However, there is a great need for studies that focus on high-risk populations, including patients who may need to. Antiplatelet therapy has been a mainstay in these patients and has been used to improve functional sta- tus, to decrease cardiovascular morbidity and mortality, and to improve patency of extremity revascularization.

General considerations for antiplatelet therapy in elderly. There is no universally accepted definition of an “elderly” patient.

The cutoff of ≥ 75 years is the most commonly used in current literature, since a significant worsening of outcome after an acute coronary event has been shown by this age.

However, lower cutoffs (60 or 65 years, intended as median population age) have also Author: Roberta De Rosa, Federico Piscione, Gennaro Galasso, Stefano De Servi, Stefano Savonitto. Alongside aspirin therapy, patients with UA or non-ST-elevation MI (NSTEMI) who are considered to have a predicted 6-month mortality of > % (which is the case for the vast majority of such patients), are typically treated with a loading dose of mg clopidogrel.

22 Those with acute ST-elevation MIs (STEMIs) will go on to receive coronary Author: Kerry Layne, Albert Ferro. Title: Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents VOLUME: 18 ISSUE: 6 Author(s):Burak Pamukcu, Kurt Huber and Gregory Y.H.

Lip Affiliation:Centre for Cardiovascular Sciences, City Hospital, B18 7QH, Birmingham, England, UK. Keywords:Atherothrombosis, cardiovascular disease, primary Cited by: 3. Dual antiplatelet therapy with aspirin and a P2Y 12 adenosine diphosphate (ADP) receptor inhibitor, such as clopidogrel or prasugrel, is the current standard-of-care antiplatelet therapy in patients with acute coronary syndromes managed with an early invasive strategy.

However, these agents are associated with several important clinical limitations, including significant residual risk for ischemic Cited by: Although the major clinical trials that have examined the efficacy of dual antiplatelet therapy in the management of post-STEMI patients have utilized treatment durations of no more than one month, dual antiplatelet therapy with clopidogrel and aspirin for periods of up to one year was estimated to be highly cost-effective (incremental cost-effectiveness ratio, €–€ per life-year gained).Cited by: 5.

Title:Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease VOLUME: 18 ISSUE: 33 Author(s):Jose Luis Ferreiro and Dominick J. Angiolillo Affiliation:University of Florida College of Medicine-Jacksonville, West 8th Street, Jacksonville, Florida, Keywords:Diabetes mellitus, platelets, coronary artery disease, antiplatelet Cited by:   Most guidelines recommend indefinite use of aspirin in patients at increased atherothrombotic risk.

Dual antiplatelet therapy (aspirin/clopidogrel) is Cited by: 5. Antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of pharmacological treatment to optimize clinical outcomes in patients Cited by: otype-guided antiplatelet therapy improved outcomes among patients undergoing PCI.

15 In this study, % of patients had a loss of function allele. Among those with a loss of function allele who received clopidogrel versus alternative antiplatelet therapy, there was a 2-fold risk of cardiovascular events, whereas there.

The benefits of antiplatelet therapy continue to be investigated. Whether dual antiplatelet therapy is superior to aspirin monotherapy for high-risk primary prevention is unknown.

The ongoing CHARISMA trial aims to determine the relative efficacies of aspirin monotherapy and aspirin/clopidogrel combination therapy in a broad range of high-risk patient by: Stroke/Embolic Risk in Patients With AF on Anticoagulation With VKAs or NOACs. In patients with AF, adjusted-dose warfarin and antiplatelet agents reduce the risk for stroke by ≈65% and by ≈20%, respectively.

17 However, oral antiplatelet agents do not perform as well as OAC with warfarin in this context. The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Cited by: Dual antiplatelet therapy (DAPT) duration: introduction.

Oral DAPT including aspirin and P2Y12 inhibitors is widely used with proven benefit for the prevention of recurrent ischemic events after acute coronary syndrome (ACS).Platelets play a central role in atherothrombosis during acute coronary syndrome (ACS) and adequate platelet inhibition is crucial to minimize the risk of recurrent Author: Pierre Deharo, Pierre Deharo, Thomas Cuisset.

Background: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.

Importance The current recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-eluting stent.

However, the optimal duration of dual antiplatelet therapy with specific types of drug-eluting stents remains unknown. Objective To assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of dual antiplatelet therapy in patients Cited by:   Dual antiplatelet therapy (DAPT) with aspirin and the P2Y purinoceptor 12 (P2Y12)-receptor inhibitor clopidogrel has been considered the gold standard of care in patients Cited by: Stroke is a leading cause of mortality and disability worldwide.

1 Initial manifestations of acute cerebral ischemia, such as ischemic stroke and transient ischemic attack (TIA), are often followed by recurrent vascular events, including recurrent stroke. 2 To reduce this burden, antiplatelet therapy is a key component of the management of noncardioembolic ischemic stroke and TIA.

3 This Cited by: 4.